Press Releases

2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010

2016
Dec 2016 | Download as pdf

Soluble Therapeutics Acquired by CytoBioscience more

Nov 2016 | Download as pdf

Young Living Essential Oils Partners with TFS Sandalwood Farms more

Nov 2016 | Download as pdf

Beaufort Memorial Using Xenex Germ-Zapping Robot to Destroy Pathogens That Can Cause Hospital-Acquired Infections more

Nov 2016 | Download as pdf

DNAtrix to Present Clinical Data at the 21st Annual Meeting of the Society for Neuro-Oncology more

Nov 2016 | Download as pdf

Cartersville Medical Center Unveils Xenex Germ-Zapping Robot more

Nov 2016 | Download as pdf

DNAtrix enters into license agreement with University of Florida to develop new oncolytic virus platform more

Nov 2016 | Download as pdf

DNAtrix Licenses Myxoma Virus for New Immunotherapy Platform more

Nov 2016 | Download as pdf

Supportive Data for the Use of Santalis Pharmaceuticals’ East Indian Sandalwood Oil (EISO) for the Treatment of Psoriasis is Presented at International Conference more

Nov 2016 | Download as pdf

Santalis Pharmaceuticals Obtains FDA Allowance To Start A Phase 2 Clinical Study For The Treatment Of Mild To Moderate Atopic Dermatitis (AD) more

Nov 2016 | Download as pdf

DNAtrix Announces First Patients Treated in Phase 2 Trial with DNX-2401 and KEYTRUDA more

Oct 2016 | Download as pdf

Robotics: Germ-Zappers Are Saving Lives more

Oct 2016 | Download as pdf

DHR first in RGV with xenon UV disinfection systems more

Oct 2016 | Download as pdf

neoSurgical® Announces CE Mark Approval of the neoClose® Laparoscopic Port Closure Device more

Oct 2016 | Download as pdf

Germ-zapping robot named 'Gronk' helped kill MRSA at Mass. high school more

Oct 2016 | Download as pdf

Doctors Hospital at Renaissance is First in Rio Grande Valley to Deploy Xenex Germ-Zapping Robots more

Oct 2016 | Download as pdf

Bio2 Medical's Angel Catheter successfully placed in first two patients more

Oct 2016 | Download as pdf

Cardiovate Develops First Bioabsorbable Vascular Graft more

Oct 2016 | Download as pdf

Funding San Antonio’s Biotech Ecosystem more

Oct 2016 | Download as pdf

A biotech groups to share in major military contract to manufacture stem cells more

Sept 2016 | Download as pdf

Robot disinfecting rooms at Life Line Hospital in Wintersville more

Sept 2016 | Download as pdf

Life Line Hospital is the First Long Term Acute Care Hospital in Ohio to Enhance Patient Safety by Deploying a Xenex Germ-Zapping Robot more

Sept 2016 | Download as pdf

Robots show Marin, Sonoma hospitals the light on disinfection more

Sept 2016 | Download as pdf

Santalis Pharmaceuticals Announces Issuance of Patent for the Use of Sandalwood Oil to Treat Cancers more

Sept 2016 | Download as pdf

Santalis Pharmaceuticals Initiates a Phase 2 Study of Mild, Moderate and Severe Atopic Dermatitis - Enrolls First Patient Into Its Australian Clinical Trial Site more

Sept 2016 | Download as pdf

With Scaffold for Regenerating Arteries, Cardiovate Raises $350,000 more

Aug 2016 | Download as pdf

Bluegrass Vascular Secures CE Mark Approval and Announces Successful Commercial Use of The Surfacer® Inside-Out® Access Catheter System more

Aug 2016 | Download as pdf

Bio2 Medical® Closes on $3 Million of Venture Debt Financing more

Aug 2016 | Download as pdf

Tropical Forestry Services prepares for first Indian sandalwood shipment to China more

Aug 2016 | Download as pdf

Bio2 Medical® Announces 510(k) Clearance from the FDA for the Angel® Catheter, the First Ever Prophylactic Use Indication for a Medical Device for Pulmonary Embolism more

Aug 2016 | Download as pdf

International perfumery competition winner tours Indian sandalwood plantations in the Kimberley more

Aug 2016 | Download as pdf

SA biotech firm drawing global interest year after moving from Germany more

Aug 2016 | Download as pdf

TFS Corporation makes bond offer more

Aug 2016 | Download as pdf

New robot system at USC Verdugo Hills Hospital uses UV light to disinfect hospital rooms more

Aug 2016 | Download as pdf

DNAtrix wins $2 million FDA grant for cancer immunotherapy more

Aug 2016 | Download as pdf

DNAtrix Awarded FDA Orphan Products Development Grant for DNX-2401 more

Aug 2016 | Download as pdf

TFS Corporation - July 2016 Update more

Aug 2016 | Download as pdf

StemBioSys reaches European distribution agreement for its products more

Aug 2016 | Download as pdf

BRIEF-Diamyd Medical: Cellaviva appointed European distributor for StemBioSys more

July 2016 | Download as pdf

DNAtrix Receives European Medicines Agency PRIME Designation more

July 2016 | Download as pdf

DNAtrix Announces Successful Intratumoral Delivery of DNX-2401 via Alcyone's MEMS Cannula for the Targeted Treatment of Recurrent Glioblastoma more

July 2016 | Download as pdf

Australia forestry company TFS Corp gets two ratings upgrades more

July 2016 | Download as pdf

Tour of Texas: Valence, Stellarray, Flux Farms, A&M, StemBioSys more

July 2016 | Download as pdf

StemBioSys reaches distribution agreement for its products in South Korea more

July 2016 | Download as pdf

Camden Clark Medical Center Introduces Newest Xenex Germ-Zapping Robot more

June 2016 | Download as pdf

MPR Client Innovative Trauma Care Wins Gold at 2016 Medical Design Excellence Awards more

June 2016 | Download as pdf

Santalis Pharmaceuticals Announces Positive Results From a Study Using 10% East Indian Sandalwood Oil (EISO) Serum Formulation for the Treatment of Mild-to-Moderate Plaque Psoriasis more

June 2016 | Download as pdf

Texas among top states in foreign investments more

June 2016 | Download as pdf

How Your Family Drives Business Decisions more

June 2016 | Download as pdf

StemBioSys enters distribution agreement for its products in Japan more

May 2016 | Download as pdf

San Antonio biotech firm takes big step toward global expansion more

May 2016 | Download as pdf

Vidant Edgecombe Hospital adds Xenex Germ-Zapping Robot to reduce HAIs more

May 2016 | Download as pdf

This hospital spent $300,000 on giant, superbug-killing robots more

May 2016 | Download as pdf

Santalis Announces First Subject Enrolled in Phase 2 Trial of East Indian Sandalwood Oil (EISO) to Treat Mild to Moderate Plaque Psoriasis more

May 2016 | Download as pdf

SA biotech company backing fed stem cell bill to cut red tape from regulatory pathway more

May 2016 | Download as pdf

Bexar County added 4,350 jobs last year, study says more

April 2016 | Download as pdf

Springfield Clinic unveils Xenex Germ-Zapping Robot for infection control more

April 2016 | Download as pdf

San Antonio venture capital funding fell last year more

April 2016 | Download as pdf

neoSurgical Limited Expands Indications For neoClose Device more

April 2016 | Download as pdf

Bio2 Medical Closes Series D Preferred Stock more

April 2016 | Download as pdf

TFS undertakes $60 million placement more

April 2016 | Download as pdf

Bluegrass Vascular Technologies’ catheter system used on first patient more

March 2016 | Download as pdf

Cytocentrics refunds $100,000 in economic development funds to city more

March 2016 | Download as pdf

Bluegrass Vascular Technologies Announces First Clinical Use of the Surfacer® Inside-Out® Access Catheter System in Europe. more

March 2016 | Download as pdf

Long-term acute care facility in California implements Xenex germ-zapping robot more

March 2016 | Download as pdf

Robotic housekeeper disinfects the rooms at Modesto hospital more

March 2016 | Download as pdf

Aerin Medical raises $16.7M, adds new board members more

March 2016 | Download as pdf

Brokers Sniff Sweet Potential In TFS Corp more

March 2016 | Download as pdf

East Indian sandalwood oil (EISO) is the key ingredient in these grooming products for dogs more

Feb 2016 | Download as pdf

Santalis Pharmaceuticals Completes the Spin-Off of Roxy’s Remedies Inc. more

Feb 2016 | Download as pdf

TFS Corporation - January 2016 Update more

Feb 2016 | Download as pdf

DNAtrix's Oncolytic Immunotherapy, DNX-2401, Awarded EU Orphan Medicine Designation more

Feb 2016 | Download as pdf

Strategic partnering deal with Cytocentrics

Cyprotex PLC (AIM:CRX), a specialist ADME-Tox and Bioscience Contract Research Organisation, today announces the signing of a strategic partnering deal with world leading ion channel specialists, Cytocentrics, Inc, to extend Cyprotex's capabilities in the in vitro ion channel screening market. As part of the agreement, Cytocentrics will provide equipment, cell lines, expertise and training to allow Cyprotex to provide a panel of different ion channel assays from its Watertown site, near Boston in the USA. 

A consortium in the USA known as CiPA (Comprehensive in Vitro Proarrythmia Assay) is currently evaluating a new paradigm for regulatory cardiac safety testing using in silico and in vitro methods. CiPA is co-sponsored by the Cardiac Safety Research Consortium (CSRC), the Health and Environmental Sciences Institute (HESI) and the US Food and Drug Administration (FDA). The in vitro methods currently being evaluated include single ion channels measurements, and integrated ion channel measurements in human stem cell-derived cardiomyocytes. Cyprotex is an active member of CiPA and plays a vital role in the development and validation of the human stem-cell derived cardiomyocyte assays using microelectrode array. This is an area in which Cyprotex has considerable expertise being the first company to launch this technology onto the market as a higher throughput platform via its eCiphr®Cardio service. The Cytocentrics agreement will complement existing technology already provided by Cyprotex by allowing Cyprotex to offer a panel of single ion channel measurements. This will enable Cyprotex to offer a fully comprehensive package of in vitro cardiac safety services which focus on key testing methods currently being addressed within the CiPA initiative.

The introduction of the new ion channel services will not only allow Cyprotex to offer cardiac safety testing but will also allow screening for potential biological effects on ion channels and so will extend Cyprotex's bioscience capabilities. The new facility, anticipated to be operational in H1 2016, is expected to contribute to the Company's performance from H2 2016 in line with current market expectations. The new services will utilise Cytocentrics CytoPatchTM4 instruments and stably transfected cell lines. The CytoPatchTM4 is an automated patch clamp system which uses a quartz glass pipette analogous to manual patch clamp and allows robust gigaseal recordings.

Anthony Baxter PhD, Chief Executive Officer of Cyprotex, comments on the agreement, 'Regulatory cardiac safety testing for new pharmaceuticals is expected to change in the near future with a greater focus on in vitroand in silico methods. Cyprotex is well placed to address this trend and will have the capability to offer a comprehensive package of in vitro cardiac services through its existing offerings and through our new partnership with Cytocentrics.'

Source: http://www.lse.co.uk back

Feb 2016 | Download as pdf

Cytocentrics CEO: San Antonio to get big boost from new deal more

Feb 2016 | Download as pdf

GhostBuster the Lab Mix Reviews Roxy’s Remedies Pure Relief Spray Gel more

Feb 2016 | Download as pdf

Avera McKennan Addresses Patient Safety with Germ-Zapping Robots more

Feb 2016 | Download as pdf

Santalis Pharmaceuticals Announces Positive Results from a Study of Pediatric Patients with Eczema more

Feb 2016 | Download as pdf

Santalis announces positive results for pediatric atopic dermatitis treatment more

Feb 2016 | Download as pdf

Here’s why the TFS Corporation Limited share price soared 28% today more

Jan 2016 | Download as pdf

Cytocentrics gaining traction in San Antonio more

Jan 2016 | Download as pdf

The Drugstore Acne Fighters Dermatologists Swear By more

Jan 2016 | Download as pdf

neoSurgical® Begins Postmarket Surveillance Study more

Jan 2016 | Download as pdf

Santalis Announces First Subject Enrolled in Phase 2 Trial more

Jan 2016 | Download as pdf

BiO2 Medical Reports Positive Advancement of the Series D Round of Funding more

Jan 2016 | Download as pdf

Germany’s Axiogenesis to collaborate with new San Antonio biotech company more